

innovative healthcare products. These comments are consistent with the United States' previous recognition that this merger has the potential to generate benefits by improving the quality and lowering the costs of healthcare services.<sup>80</sup>

**VI. Conclusion**

After careful consideration of the public comments, the United States continues to believe that the proposed Final Judgment, as drafted, provides an effective and appropriate remedy for the antitrust violations alleged in the Complaint, and is therefore in the public interest. The United States will move this Court to enter the proposed Final Judgment after the comments and this response are published as required by 15 U.S.C. § 16(d).

Dated: February 13, 2019  
Respectfully submitted,

Jay D. Owen,  
Shobitha Bhat,  
Natalie R. Melada,  
U.S. Department of Justice,  
Antitrust Division,  
450 Fifth Street NW, Suite 4100,  
Washington, D.C. 20530,  
Tel.: (202) 598-2987,  
Fax: (202) 616-2441,  
E-mail: Jay.Owen@usdoj.gov.

[FR Doc. 2019-02846 Filed 2-20-19; 8:45 am]

**BILLING CODE 4410-11-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Importer of Controlled Substances Registration**

**ACTION:** Notice of registration.

**SUMMARY:** Registrants listed below has applied for and been granted registration by the Drug Enforcement Administration (DEA) as importers of schedule I or schedule II controlled substances.

**SUPPLEMENTARY INFORMATION:** The companies listed below applied to be registered as importers of various basic classes of controlled substances. Information on the previously published notices is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for these notices.

Company	FR docket	Published
Mylan Technologies, Inc. ....	83 FR 64160	December 13, 2018.
Noramco Inc. ....	83 FR 64159	December 13, 2018.
Arizona Department of Corrections ....	83 FR 64364	December 14, 2018.

The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrants to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each company's maintenance of effective controls against diversion by inspecting and testing each company's physical security systems, verifying each company's compliance with state and local laws, and reviewing each company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I or schedule II controlled substances to the above listed companies.

Dated: January 29, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019-02871 Filed 2-20-19; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Bulk Manufacturer of Controlled Substances Application: Johnson Matthey, Inc.**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 25, 2019. Such persons may also file a written request for a hearing on the application on or before March 25, 2019.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and

implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on October 12, 2018, Johnson Matthey Inc., 2003 Nolte Drive, West Deptford, New Jersey 08066, applied to be registered as a bulk manufacturer of the following basic classes of controlled substances listed in schedule I & II.

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid.	2010	I
Marihuana .....	7360	I
Tetrahydrocannabinols.	7370	I
Dihydromorphine .....	9145	I
Difenoxin .....	9168	I
Amphetamine .....	1100	II
Methamphetamine ....	1105	II
Lisdexamfetamine ....	1205	II
Methylphenidate .....	1724	II
Nabilone .....	7379	II

<sup>80</sup> See "Justice Department Requires CVS and Aetna to Divest Aetna's Medicare Individual Part D

Prescription Drug Plan Business to Proceed with Merger," available at <https://www.justice.gov/opa/>

[pr/justice-department-requires-cvs-and-aetna-divest-aetna-s-medicare-individual-part-d.](https://www.justice.gov/opa/)

Controlled substance	Drug code	Schedule
Cocaine .....	9041	II
Codeine .....	9050	II
Dihydrocodeine .....	9120	II
Oxycodone .....	9143	II
Hydromorphone .....	9150	II
Diphenoxylate .....	9170	II
Ecgonine .....	9180	II
Hydrocodone .....	9193	II
Meperidine .....	9230	II
Methadone .....	9250	II
Methadone inter-mediate.	9254	II
Morphine .....	9300	II
Thebaine .....	9333	II
Opium tincture .....	9630	II
Oxymorphone .....	9652	II
Noroxymorphone .....	9668	II
Alfentanil .....	9737	II
Remifentanil .....	9739	II
Sufentanil .....	9740	II
Tapentadol .....	9780	II
Fentanyl .....	9801	II

below. No comments or objections were submitted for this notice.

Company	FR docket	Published
Sigma Aldrich Research.	83 FR 54613	October 30, 2018.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of this registrant to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed company.

Dated: January 29, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019-02869 Filed 2-20-19; 8:45 am]

**BILLING CODE 4410-09-P**

Company	FR docket	Published
Myoderm .....	83 FR 66751	December 27, 2018.

The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrant to import the applicable basic class of schedule II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule II controlled substances to the above listed company.

Dated: February 11, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019-02870 Filed 2-20-19; 8:45 am]

**BILLING CODE 4410-09-P**

In reference to drug codes 7360 (Marijuana), and 7370 (THC), the company plans to bulk manufacture these drugs as synthetic. No other activities for these drug codes are authorized for this registration.

Dated: February 11, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019-02882 Filed 2-20-19; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Bulk Manufacturer of Controlled Substances Registration**

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below has applied for and has been granted a registration by the Drug Enforcement Administration (DEA) as a bulk manufacturer of various classes of schedule I and II controlled substances.

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as a bulk manufacturer of various basic classes of controlled substances. Information on the previous published notice are listed in the table

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Importer of Controlled Substances Registration**

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below has applied for and has been granted registration by the Drug Enforcement Administration (DEA) as an importer of schedule II controlled substances.

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as an importer of a basic class of controlled substance. Information on the previously published notice is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for this notice.

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Importer of Controlled Substances Registration**

**ACTION:** Notice of registration.

**SUMMARY:** The registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as importers of schedule I or schedule II controlled substances.

**SUPPLEMENTARY INFORMATION:** The companies listed below applied to be registered as importers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for these notices.

Company	FR docket	Published
Janssen Pharmaceuticals, Inc .....	83 FR 58598 .....	November 20, 2018.
Lipomed .....	83 FR 58601 .....	November 20, 2018.
Akorn, Inc .....	83 FR 60896 .....	November 27, 2018.
Cambridge Isotope Laboratories .....	83 FR 60897 .....	November 27, 2018.
GE Healthcare .....	83 FR 60899 .....	November 27, 2018.
Fisher Clinical Services, Inc .....	83 FR 60900 .....	November 27, 2018.